Liposome-protein corona in a physiological environment: Challenges and opportunities for targeted delivery of nanomedicines

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 3, 2015, Pages 543-557

  Caracciolo, Giulio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Liposomes; Protein corona; Targeting

Indexed keywords

BINDING SITES; LIPOSOMES; MACHINERY; MEDICAL NANOTECHNOLOGY; MOLECULAR BIOLOGY;

CLINICAL PRACTICES; LIPOSOME ENDOCYTOSIS; PHYSIOLOGICAL ENVIRONMENT; PROTEIN CORONAS; RECEPTOR BINDING SITE; SURFACE FUNCTIONALITIES; TARGETED DELIVERY; TARGETING;

PROTEINS;

LIPOSOME; LIPOSOME PROTEIN CORONA; PROTEIN; UNCLASSIFIED DRUG; LIPOPROTEIN;

GENE TARGETING; HUMAN; LIPOSOMAL DELIVERY; NANOMEDICINE; NONHUMAN; PROTEIN BINDING; REVIEW; TARGET CELL; ANIMAL; CHEMISTRY; PROCEDURES;

ANIMALS; HUMANS; LIPOPROTEINS; LIPOSOMES; NANOMEDICINE;

EID: 84929177606     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.11.003     Document Type: Review

References (134)

1. Wang R., Billone P.S., Mullett W.M. Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials. J Nanomater 2013, 2013:1.
2. Nazir S., Hussain T., Ayub A., Rashid U., MacRobert A.J. Nanomaterials in combating cancer: therapeutic applications and developments. Nanomedicine 2013, 10:19-34.
3. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011, 8:2101-2141.
4. del Burgo L.S., Pedraz J., Orive G. Advanced nanovehicles for cancer management. Drug Discov Today 2014, 19:1659-1670.
5. Zhaorigetu S., Rodriguez-Aguayo C., Sood A.K., Lopez-Berestein G., Walton B.L. Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. J Liposome Res 2014, 1-9.
6. Domínguez A., Suárez-Merino B., Goñi-de-Cerio F. Nanoparticles and blood-brain barrier: the key to central nervous system diseases. J Nanosci Nanotechnol 2014, 14:766-779.
7. Yang Z., Chen M., Yang M., Chen J., Fang W., Xu P. Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection. Int J Nanomedicine 2014, 9:327.
8. Babar I.A., Cheng C.J., Booth C.J., Liang X., Weidhaas J.B., Saltzman W.M., et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci 2012, 109:E1695-E1704.
9. Haque M.R., Lee D.Y., Ahn C.-H., Jeong J.-H., Byun Y. Local co-delivery of pancreatic islets and liposomal clodronate using injectable hydrogel to prevent acute immune reactions in a type 1 diabetes. Pharm Res 2014, 1-10.
10. Cattaneo A.G., Gornati R., Bernardini G., Sabbioni E., Manzo L., Gioacchino M.D. Nanomedicine for the brain and the eye: disease management in poorly accessible compartments of the body. Handbook of nanotoxicology, nanomedicine and stem cell use in toxicology 2014, 223-248.
11. Kobayashi H., Watanabe R., Choyke P.L. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?. Theranostics 2014, 4:81.
12. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013, 65:36-48.
13. Fan Y., Zhang Q. Development of liposomal formulations: from concept to clinical investigations. Asian J Pharm Sci 2013, 8:81-87.
14. Al-Jamal W.T., Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res 2011, 44:1094-1104.
15. Lin Y.-Y., Kao H.-W., Li J.-J., Hwang J.-J., Tseng Y.-L., Lin W.-J., et al. Tumor burden talks in cancer treatment with PEGylated liposomal drugs. PLoS One 2013, 8:e63078.
16. Barenholz Y.C. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160:117-134.
17. Perche F., Torchilin V.P. Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv 2013, 2013.
18. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53:283-318.
19. Betker J.L., Kullberg M., Gomez J., Anchordoquy T.J. Cholesterol domains enhance transfection. Ther Deliv 2013, 4:453-462.
20. Arcamone F., Cassinelli G., Fantini G., Grein A., Orezzi P., Pol C., et al. Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 1969, 11:1101-1110.
21. Gao W., Hu C.-M.J., Fang R.H., Zhang L. Liposome-like nanostructures for drug delivery. J Mater Chem B 2013, 1:6569-6585.
22. Sahneh F.D., Scoglio C., Riviere J. Dynamics of nanoparticle-protein corona complex formation: analytical results from population balance equations. PLoS One 2013, 8:e64690.
23. Fraley R., Subramani S., Berg P., Papahadjopoulos D. Introduction of liposome-encapsulated SV40 DNA into cells. J Biol Chem 1980, 255:10431-10435.
24. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci 1987, 84:7413-7417.
25. Lappalainen K., Jääskeläinen I., Syrjänen K., Urtti A., Syrjänen S. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res 1994, 11:1127-1131.
26. Mok K., Cullis P.R. Structural and fusogenic properties of cationic liposomes in the presence of plasmid DNA. Biophys J 1997, 73:2534-2545.
27. Kircheis R., Schüller S., Brunner S., Ogris M., Heider K.H., Zauner W., et al. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J Gene Med 1999, 1:111-120.
28. Stuart D., Allen T. A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim Biophys Acta-Biomembr 2000, 1463:219-229.
29. Maurer N., Mori A., Palmer L., Monck M.A., Mok K.W., Mui B., et al. Lipid-based systems for the intracellular delivery of genetic drugs. Mol Membr Biol 1999, 16:129-140.
30. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K., et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010, 28:172-176.
31. Caracciolo G., Pozzi D., Amenitsch H., Caminiti R. Multicomponent cationic lipid-DNA complex formation: role of lipid mixing. Langmuir 2005, 21:11582-11587.
32. Caracciolo G., Caminiti R., Digman M.A., Gratton E., Sanchez S. Efficient escape from endosomes determines the superior efficiency of multicomponent lipoplexes. J Phys Chem B 2009, 113:4995-4997.
33. Pozzi D., Marchini C., Cardarelli F., Salomone F., Coppola S., Montani M., et al. Mechanistic evaluation of the transfection barriers involved in lipid-mediated gene delivery: interplay between nanostructure and composition. Biochim Biophys Acta-Biomembr 2014, 1838:957-967.
34. Bertrand N., Wu J., Xu X., Kamaly N., Farokhzad O.C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2013, 66:2-25.
35. Ogawara K.-i., Yoshizawa Y., Un K., Araki T., Kimura T., Higaki K. Nanoparticle-based passive drug targeting to tumors: considerations and implications for optimization. Biol Pharm Bull 2012, 36:698-702.
36. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
37. Danquah M.K., Zhang X.A., Mahato R.I. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev 2011, 63:623-639.
38. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
39. Chattopadhyay N., Fonge H., Cai Z., Scollard D., Lechtman E., Done S.J., et al. Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo. Mol Pharm 2012, 9:2168-2179.
40. Yu B., Tai H.C., Xue W., Lee L.J., Lee R.J. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol 2010, 27:286-298.
41. Choi C.H.J., Alabi C.A., Webster P., Davis M.E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci 2010, 107:1235-1240.
42. Debbage P. Targeted drugs and nanomedicine: present and future. Curr Pharm Des 2009, 15:153-172.
43. Guo Z., He B., Jin H., Zhang H., Dai W., Zhang L., et al. Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering. Biomaterials 2014, 35:6106-6117.
44. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010, 188:759-768.
45. Jølck R.I., Feldborg L.N., Andersen S., Moghimi S.M., Andresen T.L. Engineering liposomes and nanoparticles for biological targeting. Biofunctionalization of polymers and their applications 2011, 251-280. Springer.
46. Nellis D.F., Giardina S.L., Janini G.M., Shenoy S.R., Marks J.D., Tsai R., et al. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog 2005, 21:221-232.
47. Gaillard P.J., Appeldoorn C.C., Dorland R., van Kregten J., Manca F., Vugts D.J., et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One 2014, 9:e82331.
48. Holtman L., van Vliet E.A., Appeldoorn C., Gaillard P.J., de Boer M., Dorland R., et al. Glutathione pegylated liposomal methylprednisolone administration after the early phase of status epilepticus did not modify epileptogenesis in the rat. Epilepsy Res 2014, 108:396-404.
49. Suzuki R., Takizawa T., Kuwata Y., Mutoh M., Ishiguro N., Utoguchi N., et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm 2008, 346:143-150.
50. Goren D., Horowitz A., Zalipsky S., Woodle M., Yarden Y., Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer 1996, 74:1749.
51. Venditto V.J., Szoka F.C. Cancer nanomedicines: so many papers and so few drugs!. Adv Drug Deliv Rev 2013, 65:80-88.
52. Kim S.K., Foote M.B., Huang L. The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticles. Biomaterials 2012, 33:3959-3966.
53. Walkey C.D., Chan W.C.W. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev 2012, 41:2780-2799.
54. Caracciolo G., Cardarelli F., Pozzi D., Salomone F., Maccari G., Bardi G., et al. Selective targeting capability acquired with a protein corona adsorbed on the surface of 1, 2-dioleoyl-3-trimethylammonium propane/DNA nanoparticles. ACS Appl Mater Interfaces 2013, 5:13171-13179.
55. Gaspar R. Nanoparticles: pushed off target with proteins. Nat Nanotechnol 2013, 8:79-80.
56. Mirshafiee V., Mahmoudi M., Lou K., Cheng J., Kraft M.L. Protein corona significantly reduces active targeting yield. Chem Commun 2013, 49:2557-2559.
57. Salvati A., Pitek A.S., Monopoli M.P., Prapainop K., Bombelli F.B., Hristov D.R., et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013, 8:137-143.
58. Tenzer S., Docter D., Kuharev J., Musyanovych A., Fetz V., Hecht R., et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol 2013, 8:772-781.
59. Diederichs J.E. Plasma protein adsorption patterns on liposomes: establishment of analytical procedure. Electrophoresis 1996, 17:607-611.
60. Lück M., Paulke B.R., Schröder W., Blunk T., Müller R. Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J Biomed Mater Res 1998, 39:478-485.
61. Zelphati O., Uyechi L.S., Barron L.G., Szoka F.C. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid. Metabolism 1998, 1390:119-133.
62. Cedervall T., Lynch I., Foy M., Berggård T., Donnelly S.C., Cagney G., et al. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew Chem Int Ed 2007, 46:5754-5756.
63. Lundqvist M., Stigler J., Elia G., Lynch I., Cedervall T., Dawson K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci 2008, 105:14265-14270.
64. Lynch I., Dawson K.A. Protein-nanoparticle interactions. Nano Today 2008, 3:40-47.
65. Minchin R. Nanomedicine: sizing up targets with nanoparticles. Nat Nanotechnol 2008, 3:12-13.
66. Lynch I., Salvati A., Dawson K.A. Protein-nanoparticle interactions: what does the cell see?. Nat Nanotechnol 2009, 4:546-547.
67. Caracciolo G., Callipo L., De Sanctis S.C., Cavaliere C., Pozzi D., Laganà A. Surface adsorption of protein corona controls the cell internalization mechanism of DC-Chol-DOPE/DNA lipoplexes in serum. Biochim Biophys Acta Biomembr 2010, 1798:536-543.
68. Dell'Orco D., Lundqvist M., Oslakovic C., Cedervall T., Linse S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS One 2010, 5:e10949.
69. Lundqvist M., Stigler J., Cedervall T., Berggård T., Flanagan M.B., Lynch I., et al. The evolution of the protein corona around nanoparticles: a test study. ACS Nano 2011, 5:7503-7509.
70. Mahmoudi M., Laurent S., Shokrgozar M.A., Hosseinkhani M. Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell "vision" versus physicochemical properties of nanoparticles. ACS Nano 2011, 5:7263-7276.
71. Dell'Orco D., Lundqvist M., Cedervall T., Linse S. Delivery success rate of engineered nanoparticles in the presence of the protein corona: a systems-level screening. Nanomedicine 2012, 8:1271-1281.
72. Mahmoudi M., Saeedi-Eslami S.N., Shokrgozar M.A., Azadmanesh K., Hassanlou M., Kalhor H.R., et al. Cell "vision": complementary factor of protein corona in nanotoxicology. Nanoscale 2012, 4:5461-5468.
73. Mahon E., Salvati A., Baldelli Bombelli F., Lynch I., Dawson K.A. Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". J Control Release 2012, 161:164-174.
74. Milani S., Baldelli Bombelli F., Pitek A.S., Dawson K.A., Rädler J. Reversible versus irreversible binding of transferrin to polystyrene nanoparticles: soft and hard corona. ACS Nano 2012, 6:2532-2541.
75. Monopoli M.P., Åberg C., Salvati A., Dawson K.A. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol 2012, 7:779-786.
76. Rocks L., Dawson K.A.. The interaction between nanoparticles and biological barriers. Eur J Nanomed 2014, 6:121-122.
77. Lundqvist M. Nanoparticles: tracking protein corona over time. Nat Nanotechnol 2013, 8:701-702.
78. Mahmoudi M., Abdelmonem A.M., Behzadi S., Clement J.H., Dutz S., Ejtehadi M.R., et al. Temperature: the "ignored" factor at the NanoBio interface. ACS Nano 2013, 7:6555-6562.
79. Amenitsch H., Caracciolo G., Foglia P., Fuscoletti V., Giansanti P., Marianecci C., et al. Existence of hybrid structures in cationic liposome/DNA complexes revealed by their interaction with plasma proteins. Colloids Surf B: Biointerfaces 2011, 82:141-146.
80. Capriotti A.L., Caracciolo G., Caruso G., Foglia P., Pozzi D., Samperi R., et al. Differential analysis of "protein corona" profile adsorbed onto different nonviral gene delivery systems. Anal Biochem 2011, 419:180-189.
81. Caracciolo G., Pozzi D., Candeloro De Sanctis S., Laura Capriotti A., Caruso G., Samperi R., et al. Effect of membrane charge density on the protein corona of cationic liposomes: interplay between cationic charge and surface area. Appl Phys Lett 2011, 99.
82. Caracciolo G., Pozzi D., Capriotti A.L., Cavaliere C., Foglia P., Amenitsch H., et al. Evolution of the protein corona of lipid gene vectors as a function of plasma concentration. Langmuir 2011, 27:15048-15053.
83. Capriotti A.L., Caracciolo G., Cavaliere C., Foglia P., Pozzi D., Samperi R., et al. Do plasma proteins distinguish between liposomes of varying charge density?. J Proteome 2012, 75:1924-1932.
84. Caracciolo G. The protein corona effect for targeted drug delivery. Bioinspired Biomimetic Nanobiomater 2012, 2:54-57.
85. Capriotti A.L., Caracciolo G., Caruso G., Cavaliere C., Pozzi D., Samperi R., et al. Label-free quantitative analysis for studying the interactions between nanoparticles and plasma proteins. Anal Bioanal Chem 2013, 405:635-645.
86. Walczyk D., Bombelli F.B., Monopoli M.P., Lynch I., Dawson K.A. What the cell "sees" in bionanoscience. J Am Chem Soc 2010, 132:5761-5768.
87. Capriotti A.L., Caracciolo G., Caruso G., Foglia P., Pozzi D., Samperi R., et al. DNA affects the composition of lipoplex protein corona: a proteomics approach. Proteomics 2011, 11:3349-3358.
88. Capriotti A.L., Caracciolo G., Cavaliere C., Crescenzi C., Pozzi D., Laganà A. Shotgun proteomic analytical approach for studying proteins adsorbed onto liposome surface. Anal Bioanal Chem 2011, 401:1195-1202.
89. Caracciolo G., Pozzi D., Capriotti A.L., Marianecci C., Carafa M., Marchini C., et al. Factors determining the superior performance of lipid/DNA/protammine nanoparticles over lipoplexes. J Med Chem 2011, 54:4160-4171.
90. Barran Berdon A.L., Pozzi D., Caracciolo G., Capriotti A.L., Caruso G., Cavaliere C., et al. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. Langmuir 2013, 29:6485-6494.
91. Caracciolo G., Cardarelli F., Pozzi D., Salomone F., Maccari G., Bardi G., et al. Selective targeting capability acquired with a protein corona adsorbed on the surface of DOTAP/DNA nanoparticles. ACS Appl Mater Interfaces 2013, 5:13171-13179.
92. Caracciolo G., Pozzi D., Capriotti A.L., Cavaliere C., Laganà A. Effect of DOPE and cholesterol on the protein adsorption onto lipid nanoparticles. J Nanoparticle Res 2013, 15.
93. Pozzi D., Colapicchioni V., Caracciolo G., Piovesana S., Capriotti A.L., Palchetti S., et al. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. Nanoscale 2014, 6:2782-2792.
94. Monopoli M.P., Walczyk D., Campbell A., Elia G., Lynch I., Baldelli Bombelli F., et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 2011, 133:2525-2534.
95. Caracciolo G., Pozzi D., Capriotti A.L., Cavaliere C., Piovesana S., La Barbera G., et al. The liposome-protein corona in mice and humans and its implications for in vivo delivery. J Mater Chem B 2014, 2:7419-7428.
96. Hajipour M.J., Laurent S., Aghaie A., Rezaee F., Mahmoudi M. Personalized protein coronas: a "key" factor at the nanobiointerface. Biomater Sci 2014, 2:1210-1221.
97. Caracciolo G., Caputo D., Pozzi D., Colapicchioni V., Coppola R. Size and charge of nanoparticles following incubation with human plasma of healthy and pancreatic cancer patients. Colloids Surf B Biointerfaces 2014, 123:673-678.
98. Sempf K., Arrey T., Gelperina S., Schorge T., Meyer B., Karas M., et al. Adsorption of plasma proteins on uncoated PLGA nanoparticles. Eur J Pharm Biopharm 2013, 85:53-60.
99. Caracciolo G., Pozzi D., Capriotti A.L., Cavaliere C., Piovesana S., La Barbera G., et al. The liposome-protein corona in mice and humans and its implications for in vivo delivery. J Mater Chem B 2014, 2:7419-7428.
100. Simberg D., Park J.-H., Karmali P.P., Zhang W.-M., Merkulov S., McCrae K., et al. Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials 2009, 30:3926-3933.
101. Andersen A.J., Hashemi S.H., Andresen T.L., Hunter A.C., Moghimi S.M. Complement: alive and kicking nanomedicines. J Biomed Nanotechnol 2009, 5:364-372.
102. Szebeni J., Moghimi S.M. Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions: biological recognition and interactions of liposomes. J Liposome Res 2009, 19:85-90.
103. Gabizon A.A., Barenholz Y., Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993, 10:703-708.
104. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994, 54:987-992.
105. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmacokinet 2003, 42:419-436.
106. Pasut G., Veronese F.M. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release 2012, 161:461-472.
107. Moghimi S., Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003, 42:463-478.
108. Zhao Y., Wang C., Wang L., Yang Q., Tang W., She Z., et al. A frustrating problem: accelerated blood clearance of PEGylated solid lipid nanoparticles following subcutaneous injection in rats. Eur J Pharm Biopharm 2012, 81:506-513.
109. Verhoef J.J., Anchordoquy T.J. Questioning the use of PEGylation for drug delivery. Drug Deliv Transl Res 2013, 3:499-503.
110. Walkey C.D., Olsen J.B., Guo H., Emili A., Chan W.C. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc 2012, 134:2139-2147.
111. Monopoli M.P., Bombelli F.B., Dawson K.A. Nanobiotechnology: nanoparticle coronas take shape. Nat Nanotechnol 2010, 6:11-12.
112. Tenzer S., Docter D., Rosfa S., Wlodarski A., Kuharev J., Rekik A., et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 2011, 5:7155-7167.
113. Barrán-Berdón A.L., Pozzi D., Caracciolo G., Capriotti A.L., Caruso G., Cavaliere C., et al. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. Langmuir 2013, 29:6485-6494.
114. Kwon O.-J., Kang E., Kim S., Yun C.-O. Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery. J Control Release 2011, 155:317-325.
115. Lai Z.W., Yan Y., Caruso F., Nice E.C. Emerging techniques in proteomics for probing nano-bio interactions. ACS Nano 2012, 6:10438-10448.
116. Capriotti A.L., Caracciolo G., Caruso G., Cavaliere C., Pozzi D., Samperi R., et al. Analysis of plasma protein adsorption onto DC-Chol-DOPE cationic liposomes by HPLC-CHIP coupled to a Q-TOF mass spectrometer. Anal Bioanal Chem 2010, 398:2895-2903.
117. Dell'Orco D., Lundqvist M., Linse S., Cedervall T. Mathematical modeling of the protein corona: implications for nanoparticulate delivery systems. Nanomedicine 2014, 9:851-858.
118. Yokoe J.-i., Sakuragi S., Yamamoto K., Teragaki T., Ogawara K.-i., Higaki K., et al. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. Int J Pharm 2008, 353:28-34.
119. Mortimer G.M., Butcher N.J., Musumeci A.W., Deng Z.J., Martin D.J., Minchin R.F. Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials. ACS Nano 2014, 8:3357-3366.
120. Fleischer C.C., Payne C.K. Nanoparticle surface charge mediates the cellular receptors used by protein-nanoparticle complexes. J Phys Chem B 2012, 116:8901-8907.
121. Dittrich C., Burckhardt C.J., Danuser G. Delivery of membrane impermeable cargo into CHO cells by peptide nanoparticles targeted by a protein corona. Biomaterials 2012, 33:2746-2753.
122. Prapainop K., Witter D.P., Wentworth P. A chemical approach for cell-specific targeting of nanomaterials: small-molecule-initiated misfolding of nanoparticle corona proteins. J Am Chem Soc 2012, 134:4100-4103.
123. Deng Z.J., Liang M., Monteiro M., Toth I., Minchin R.F. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat Nanotechnol 2011, 6:39-44.
124. Kim S.I., Shin D., Lee H., Ahn B.-Y., Yoon Y., Kim M. Targeted delivery of siRNA against hepatitis C virus by apolipoprotein AI-bound cationic liposomes. J Hepatol 2009, 50:479-488.
125. Williams K., Werth V., Wolff J. Intravenously administered lecithin liposomes: a synthetic antiatherogenic lipid particle. Perspect Biol Med 1984, 27:417.
126. Bisgaier C.L., Siebenkas M.V., Williams K.J. Effects of apolipoproteins A-IV and AI on the uptake of phospholipid liposomes by hepatocytes. J Biol Chem 1989, 264:862-866.
127. Morita S.Y., Sakurai A., Nakano M., Kitagawa S., Handa T. Presence of apolipoprotein C-III attenuates apolipoprotein E-mediated cellular uptake of cholesterol-containing lipid particles by HepG2 cells. Lipids 2011, 46:323-332.
128. Arvizo R.R., Giri K., Moyano D., Miranda O.R., Madden B., McCormick D.J., et al. Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One 2012, 7:e33650.
129. Pozzi D., Caracciolo G., Capriotti A.L., Cavaliere C., Piovesana S., Colapicchioni V., et al. A proteomics-based methodology to investigate the protein corona effect for targeted drug delivery. Mol BioSyst 2014, 10:2815-2819.
130. Pozzi D., Marchini C., Cardarelli F., Rossetta A., Colapicchioni V., Amici A., et al. Mechanistic understanding of gene delivery mediated by highly efficient multicomponent envelope-type nanoparticle systems. Mol Pharm 2013, 10:4654-4665.
131. Coppola S., Pozzi D., Sanctis S.C.D., Digman M.A., Gratton E., Caracciolo G. Quantitative measurement of intracellular transport of nanocarriers by spatio-temporal image correlation spectroscopy. Methods Appl Fluoresc 2013, 1:015005.
132. Cardarelli F., Pozzi D., Bifone A., Marchini C., Caracciolo G. Cholesterol-dependent macropinocytosis and endosomal escape control the transfection efficiency of lipoplexes in CHN living cells. Mol Pharm 2012, 9:334-340.
133. Pozzi D., Marchini C., Cardarelli F., Amenitsch H., Garulli C., Bifone A., et al. Transfection efficiency boost of cholesterol-containing lipoplexes. Biochim Biophys Acta Biomembr 1818, 2012:2335-2343.
134. Laurent S., Burtea C., Thirifays C., Häfeli U.O., Mahmoudi M. Crucial ignored parameters on nanotoxicology: the importance of toxicity assay modifications and "cell vision". PLoS One 2012, 7:e29997.